Skip to main content
TipRanks
Go Ultimate75% OFF

Ovid Therapeutics (OVID) Stock Statistics & Valuation Metrics

1,782 Followers

Total Valuation

Ovid Therapeutics has a market cap or net worth of $479.38M. The enterprise value is $381.28M.

Market Cap
$479.38M
Enterprise Value
$381.28M

Share Statistics

Ovid Therapeutics has 188,731,920 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
188,731,920
Owned by Insiders
6.96%
Owned by Institutions
44.14%

Financial Efficiency

Ovid Therapeutics’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -29.46%.

Return on Equity (ROE)
-0.13
Return on Assets (ROA)
-0.12
Return on Invested Capital (ROIC)
-29.46%
Return on Capital Employed (ROCE)
-0.30
Revenue Per Employee
315.30K
Profits Per Employee
-757.13K
Employee Count
23
Asset Turnover
0.05
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Ovid Therapeutics is -6.20. Ovid Therapeutics’s PEG ratio is 0.21.

PE Ratio
-6.20
PS Ratio
330.38
PB Ratio
2.60
Price to FCF
-8.30
Price to Operating Cash Flow
-8.93
PEG Ratio
0.21

Income Statement

In the last 12 months, Ovid Therapeutics had revenue of 7.25M and earned -17.41M in profits. Earnings per share was -0.24.

Revenue
7.25M
Gross Profit
6.95M
Operating Income
-42.44M
Pretax Income
-17.41M
Net Income
-17.41M
EBITDA
-17.14M
Earnings Per Share (EPS)
-0.24

Cash Flow

In the last 12 months, operating cash flow was -57.78M and capital expenditures 0, giving a free cash flow of -57.78M billion.

Operating Cash Flow
-57.78M
Free Cash Flow
-57.78M
Free Cash Flow per Share
-0.28

Dividends & Yields

Ovid Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-12.05%
Earnings Yield
-8.36%

Stock Price Statistics

Beta
1.80
52-Week Price Change
111.67%
50-Day Moving Average
2.51
200-Day Moving Average
2.42
Relative Strength Index (RSI)
50.17
Average Volume (3m)
1.93M

Important Dates

Ovid Therapeutics upcoming earnings date is Mar 15, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 10, 2026
Next Earnings Date
Mar 15, 2027
Ex-Dividend Date
―

Financial Position

Ovid Therapeutics as a current ratio of 10.91, with Debt / Equity ratio of 10.27%

Current Ratio
10.91
Quick Ratio
10.91
Debt to Market Cap
0.00
Net Debt to EBITDA
-0.02
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Ovid Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Ovid Therapeutics EV to EBITDA ratio is -10.87, with an EV/FCF ratio of -8.27.

EV to Sales
329.37
EV to EBITDA
-10.87
EV to Free Cash Flow
-8.27
EV to Operating Cash Flow
-8.27

Balance Sheet

Ovid Therapeutics has $136.60M in cash and marketable securities with $12.35M in debt, giving a net cash position of $124.25M billion.

Cash & Marketable Securities
$136.60M
Total Debt
$12.35M
Net Cash
$124.25M
Net Cash Per Share
$0.66
Tangible Book Value Per Share
$0.98

Margins

Gross margin is 100.00%, with operating margin of -4700.28%, and net profit margin of -2971.33%.

Gross Margin
100.00%
Operating Margin
-4700.28%
Pretax Margin
-2971.33%
Net Profit Margin
-2971.33%
EBITDA Margin
-3029.22%
EBIT Margin
-3057.27%

Analyst Forecast

The average price target for Ovid Therapeutics is $5.64, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$5.64
Price Target Upside
122.16% Upside
Analyst Consensus
Strong Buy
Analyst Count
7
Revenue Growth Forecast
-78.05%
EPS Growth Forecast
63.85%

Scores

Smart Score
9
AI Score
52